COMP <GO>
PAHC vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: PAHC 4
— MRK 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
roic
9.90%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.90% | 74.80% | -43.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 9.90% | 20.70% | -10.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.2x | 15.3x | +3.90 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 3.42% | +1.66 | PAHC | /fcf-yield <GO> |
| Operating Margin | 8.50% | 34.30% | -25.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 28.10% | -24.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | 1.30% | +26.10 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 2.26% | -1.03 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | 5.19 | -2.32 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.8 | 51.7 | +5.10 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | 18.4x | +9.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $361.02B | -$359.44B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | MRK REV | PAHC GROSS % | MRK GROSS % | PAHC FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $65.01B | 30.9% | 74.8% | $80.1M | $12.36B |
| FY 2024 | $1.02B | $64.17B | 30.8% | 76.3% | $87.6M | $18.10B |
| FY 2023 | $977.9M | $60.12B | — | — | $13.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
MRK // BETA 0.92